IL190585A - Method for the diagnosis of thromboembolic and coronary heart diseases - Google Patents
Method for the diagnosis of thromboembolic and coronary heart diseasesInfo
- Publication number
- IL190585A IL190585A IL190585A IL19058508A IL190585A IL 190585 A IL190585 A IL 190585A IL 190585 A IL190585 A IL 190585A IL 19058508 A IL19058508 A IL 19058508A IL 190585 A IL190585 A IL 190585A
- Authority
- IL
- Israel
- Prior art keywords
- egln2
- coronary heart
- myocardial infarction
- risk
- thromboembolic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 39
- 208000029078 coronary artery disease Diseases 0.000 title claims description 35
- 208000001435 Thromboembolism Diseases 0.000 title claims description 21
- 230000009424 thromboembolic effect Effects 0.000 title claims description 18
- 238000003745 diagnosis Methods 0.000 title claims description 8
- 101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 claims description 57
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 claims description 35
- 208000010125 myocardial infarction Diseases 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 102000048660 human EGLN2 Human genes 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 208000006011 Stroke Diseases 0.000 claims description 13
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 229940104230 thymidine Drugs 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 210000002889 endothelial cell Anatomy 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 238000003203 nucleic acid sequencing method Methods 0.000 claims description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 4
- 206010050496 Reversible ischaemic neurological deficit Diseases 0.000 claims description 3
- 239000013611 chromosomal DNA Substances 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 108020003215 DNA Probes Proteins 0.000 claims description 2
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 239000003298 DNA probe Substances 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 238000002105 Southern blotting Methods 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 238000012175 pyrosequencing Methods 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
- 229940045145 uridine Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 230000007614 genetic variation Effects 0.000 description 5
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 102100037249 Egl nine homolog 1 Human genes 0.000 description 3
- 101000881678 Homo sapiens Prolyl hydroxylase EGLN3 Proteins 0.000 description 3
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 3
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 3
- 101710170760 Prolyl hydroxylase EGLN2 Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000020874 response to hypoxia Effects 0.000 description 2
- 102200148363 rs672601362 Human genes 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710111663 Egl nine homolog 1 Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710170720 Prolyl hydroxylase EGLN3 Proteins 0.000 description 1
- 244000078856 Prunus padus Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000019039 oxygen homeostasis Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005048899A DE102005048899A1 (de) | 2005-10-12 | 2005-10-12 | Verfahren zur Diagnose thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| PCT/EP2006/009517 WO2007042165A1 (de) | 2005-10-12 | 2006-09-30 | Verfahren zur diagnose thromboembolischer erkrankungen und koronarer herzerkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL190585A0 IL190585A0 (en) | 2008-11-03 |
| IL190585A true IL190585A (en) | 2011-12-29 |
Family
ID=37684083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL190585A IL190585A (en) | 2005-10-12 | 2008-04-02 | Method for the diagnosis of thromboembolic and coronary heart diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090197774A1 (enExample) |
| EP (1) | EP1937839B1 (enExample) |
| JP (1) | JP2009511026A (enExample) |
| KR (1) | KR20080052662A (enExample) |
| CN (1) | CN101287846A (enExample) |
| AR (1) | AR056125A1 (enExample) |
| AT (1) | ATE525481T1 (enExample) |
| AU (1) | AU2006301578B9 (enExample) |
| BR (1) | BRPI0617341A2 (enExample) |
| CA (1) | CA2625698A1 (enExample) |
| DE (1) | DE102005048899A1 (enExample) |
| IL (1) | IL190585A (enExample) |
| TW (1) | TW200734638A (enExample) |
| WO (1) | WO2007042165A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005048898A1 (de) * | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| EP2311981B1 (en) | 2007-05-01 | 2014-09-17 | The Regents of The University of California | Methods for diagnosing ischemia |
| US20120015904A1 (en) * | 2010-07-14 | 2012-01-19 | Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
| CA2804802C (en) | 2010-07-15 | 2023-03-07 | The Regents Of The University Of California | Biomarkers for diagnosis of stroke and its causes |
| US20120316076A1 (en) | 2011-03-04 | 2012-12-13 | The Regents Of The University Of California | Biomarkers for the diagnosis of lacunar stroke |
| CA2856461C (en) * | 2011-12-01 | 2020-08-18 | F. Hoffmann-La Roche Ag | Nt-proanp and nt-probnp for the diagnosis of stroke |
| WO2013103781A1 (en) | 2012-01-07 | 2013-07-11 | The Regents Of The University Of California | Biomarkers for diagnosing ischemia |
| KR101939778B1 (ko) | 2012-07-27 | 2019-01-18 | 삼성전자주식회사 | 필요 혈류량 결정 방법 및 장치, 혈류 영상 생성 방법 및 장치, 심근 관류 영상 처리 방법 및 장치 |
| CN119846215B (zh) * | 2025-01-22 | 2025-07-11 | 广西医科大学附属肿瘤医院 | Egln1乳酸化作为靶点在制备肿瘤诊断试剂盒或治疗药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2474630B1 (en) * | 2002-12-20 | 2016-04-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| CA2510895A1 (en) * | 2002-12-20 | 2004-07-15 | Applera Corporation | Genetic polymorphisms associated with stenosis, methods of detection and uses thereof |
-
2005
- 2005-10-12 DE DE102005048899A patent/DE102005048899A1/de not_active Withdrawn
-
2006
- 2006-09-30 US US12/089,624 patent/US20090197774A1/en not_active Abandoned
- 2006-09-30 JP JP2008534895A patent/JP2009511026A/ja not_active Abandoned
- 2006-09-30 WO PCT/EP2006/009517 patent/WO2007042165A1/de not_active Ceased
- 2006-09-30 BR BRPI0617341-1A patent/BRPI0617341A2/pt not_active Application Discontinuation
- 2006-09-30 CA CA002625698A patent/CA2625698A1/en not_active Withdrawn
- 2006-09-30 EP EP06792341A patent/EP1937839B1/de not_active Not-in-force
- 2006-09-30 AT AT06792341T patent/ATE525481T1/de active
- 2006-09-30 KR KR1020087008790A patent/KR20080052662A/ko not_active Withdrawn
- 2006-09-30 AU AU2006301578A patent/AU2006301578B9/en not_active Withdrawn - After Issue
- 2006-09-30 CN CNA2006800376009A patent/CN101287846A/zh active Pending
- 2006-10-05 TW TW095136992A patent/TW200734638A/zh unknown
- 2006-10-10 AR ARP060104446A patent/AR056125A1/es unknown
-
2008
- 2008-04-02 IL IL190585A patent/IL190585A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101287846A (zh) | 2008-10-15 |
| TW200734638A (en) | 2007-09-16 |
| AR056125A1 (es) | 2007-09-19 |
| IL190585A0 (en) | 2008-11-03 |
| AU2006301578B2 (en) | 2011-12-01 |
| ATE525481T1 (de) | 2011-10-15 |
| WO2007042165A1 (de) | 2007-04-19 |
| US20090197774A1 (en) | 2009-08-06 |
| AU2006301578B9 (en) | 2011-12-22 |
| AU2006301578A1 (en) | 2007-04-19 |
| EP1937839A1 (de) | 2008-07-02 |
| CA2625698A1 (en) | 2007-04-19 |
| JP2009511026A (ja) | 2009-03-19 |
| EP1937839B1 (de) | 2011-09-21 |
| DE102005048899A1 (de) | 2007-04-19 |
| BRPI0617341A2 (pt) | 2011-07-26 |
| KR20080052662A (ko) | 2008-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190585A (en) | Method for the diagnosis of thromboembolic and coronary heart diseases | |
| US20030077629A1 (en) | Genotyping human UDP-Glucuronsyltransferase 2B15 (UGT2B15) genes | |
| JP2003535601A (ja) | ヒトチトクロムｐ４５０２ａ６遺伝子の遺伝子型決定と関連物質および方法 | |
| US20030170674A1 (en) | Nitric oxide synthase gene diagnostic polymorphisms | |
| Fujihara et al. | Frequency of a single nucleotide (A2317G) and 56-bp variable number of tandem repeat polymorphisms within the deoxyribonuclease I gene in five ethnic populations. | |
| CA2675606A1 (en) | Diagnostic marker and platform for drug design in myocardial infarction and heart failure | |
| JP3682688B2 (ja) | 骨粗鬆症薬剤感受性予測方法およびそのための試薬キット | |
| JP4728949B2 (ja) | 心臓血管疾患の危険を評価するためのｐａｒ１多型の解析および使用 | |
| JP2001516592A (ja) | ミクロソームトリグリセリド転移タンパク質プロモーターにおける遺伝学的多型及びその使用 | |
| JP4444576B2 (ja) | ２型糖尿病関連遺伝子 | |
| JP2003245087A (ja) | 遺伝子診断方法 | |
| HK1125414A (en) | Method for diagnosing thromboembolic disorders and coronary heart diseases | |
| CN102443630A (zh) | 人ppp2r3a基因突变及其用途 | |
| US20020034742A1 (en) | Disease association by stratification | |
| JP4845486B2 (ja) | 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法 | |
| US20140051074A1 (en) | Method of judging inflammatory disease by using single nucleotide polymorphism | |
| JP3684921B2 (ja) | 骨粗鬆症薬剤感受性予測方法 | |
| JP5111763B2 (ja) | 気管支喘息の遺伝的素因検査方法 | |
| WO2000061811A2 (en) | Method of predicting susceptibility to hiv infection or progression of hiv disease | |
| JP5235448B2 (ja) | 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法 | |
| JP4111482B2 (ja) | 循環器疾患の遺伝的要因を判定するための方法及びこれに使用されるオリゴヌクレオチド | |
| Eminović et al. | New steroid 5α-reductase type I (SRD5A1) homologous sequences on human chromosomes 6 and 8 | |
| JP2000175689A (ja) | ヒトミトコンドリアｄｎａ異常の検出方法 |